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AbstrACt
Objective To determine the feasibility of a randomised 
controlled trial (RCT) of rhinothermy for the common cold.
Design Open label, randomised, controlled feasibility 
study.
setting Single-centre research institute in New Zealand 
recruiting participants from the community.
Participants 30 adult participants with symptoms of a 
common cold, presenting within 48 hours of the onset of 
symptoms.
Interventions Participants were randomly assigned 2:1 
to receive either 35 L/min of 100% humidified air at 41°C 
via high flow nasal cannulae, 2 hours per day for up to 
5 days (rhinothermy), or vitamin C 250 mg daily for 5 days 
(control).
Primary and secondary outcome measures The 
primary outcome was the proportion of screened 
candidates who were randomised. Secondary outcomes 
included: proportion of randomised participants who 
completed the study; modified Jackson scores from 
randomisation to 10 days after initiation of randomised 
regimen; time until feeling ‘a lot better’ compared with 
study entry; time until resolution of symptoms or symptom 
score at 10 days postrandomisation; proportion of 
organisms identified by PCR analysis of nasal swabs taken 
at baseline; the patterns of use of the rhinothermy device; 
estimated adherence of the control group; and rhinothermy 
device tolerability.
results In all 30/79 (38%, 95% CI 27% to 50%) of 
potential participants screened for eligibility were 
randomised. Rhinothermy was well tolerated, and all 
randomised participants completed the study (100%, 
95% CI 88% to 100%). The reduction from baseline in the 
modified Jackson score was greater with rhinothermy 
compared with control at days 2, 3, 4, 5 and 6, with the 
maximum difference at day 4 (−6.4, 95% CI −9.4 to −3.3). 
The substantial clinical benefit threshold for modified 
Jackson score was a 5-unit change.
Conclusions This study shows that an RCT of 
rhinothermy compared with low-dose vitamin C in the 
treatment of the common cold is feasible.
trial registration number ACTRN12616000470493; 
Results.
IntrODuCtIOn 
The common cold is the most frequent infec-
tion worldwide. Adults report between two 
and four colds a year and children between 
six and eight colds a year.1 The median incu-
bation period depends on the virus but is 
usually between 1 and 6 days.2 The severity 
of symptoms typically peaks 3 to 3 days after 
symptom onset.1 It is almost always a self-lim-
iting illness, and the total symptom dura-
tion is between 7 and 14 days.3 Historical 
estimates put the total cost of the common 
cold in the USA as high as $40 billion per 
year.4 This includes both healthcare resource 
use and work productivity losses, the latter 
approaching $25 billion.5 About one half of 
common colds are caused by human rhino-
virus (HRV),3 6 although in autumn, HRV 
may account for 80% of all upper respira-
tory tract infections.6 HRV is strongly asso-
ciated with exacerbations of asthma in both 
children and adults and causes more severe 
and long-lasting symptoms in these patient 
groups.7 Respiratory viruses, including HRV, 
are found in 40% of exacerbations in patients 
with chronic obstructive pulmonary disease 
(COPD).8 
strengths and limitations of this study
 ► This is the first study investigating the use of rhino-
thermy delivered via high flow nasal cannulae for 
the treatment of the common cold.
 ► This open-label, randomised controlled feasibility 
study shows that a randomised controlled trial of 
rhinothermy compared with low-dose vitamin C in 
the treatment of the common cold is feasible.
 ► A 5-unit change in modified Jackson score has been 
estimated to represent the threshold for substantial 
clinical benefit.
 ► Although this study suggested a benefit from rhino-
thermy, this finding should be considered with cau-
tion, as this was a feasibility study in which efficacy 
was not the primary outcome measure.
 ► A robust adequately powered RCT is needed, par-
ticularly as this feasibility study identified that rhi-
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Treatment for the common cold is supportive and 
symptomatic. About two-thirds of those with a cold use 
‘over the counter’ products.4 Treatments that have not 
shown benefit in the treatment of the common cold 
include: echinacea, antihistamines, intranasal corticoste-
roids, antivirals and antibiotics.3 9–12 Regular supplemen-
tation with vitamin C has a small effect on cold duration, 
but therapeutic supplementation once symptoms develop 
lacks evidence of efficacy,13 and it is unlikely that supple-
mentation with low-dose vitamin C once symptomatic will 
reduce symptom severity or duration. There is no effec-
tive HRV vaccine, in part because of the high sequence 
variability in the antigenic sites of the 150 distinct HRV 
serotypes.14
Steam inhalation for symptom relief is a traditional 
remedy for the common cold. There is a scientific ratio-
nale for this treatment because HRV is a temperature-sen-
sitive virus with temperature-dependent reduction in viral 
replication between 33°C and 43°C in vitro.15–18 Host 
defence may also be enhanced at higher temperatures 
through mechanisms, such as greater production and 
responsiveness to interferon,19 20 and enhanced antiviral 
immune responses mediated by heat shock proteins.15 
Clinical studies of the efficacy of heated humidified air 
delivered at high flow to the upper airways (rhinothermy) 
report inconsistent results.16 21–25 Study limitations 
include variable, and likely ineffective, methods of deliv-
ering heated humid air at high flow to the upper airways. 
These methods include delivery through nozzles held 
a distance away from the nares and vented anaesthetic 
masks. The reported intervention durations were also 
variable. A Cochrane Review assessed that the current 
evidence could not support or refute effectiveness and 
recommended that there is a need for robustly designed 
and adequately powered randomised controlled trials 
(RCTs) to assess the effectiveness of rhinothermy to treat 
the common cold.21
We have reported a tolerability study that found that 
a high flow nasal cannula device (myAIRVO 2, Fisher & 
Paykel Healthcare, Auckland, New Zealand) modified 
to deliver high flow humidified air at 41°C via wide bore 
nasal cannulae was well tolerated in healthy volunteers.26 
The potential advantage of this device for rhinothermy 
is that it can deliver a consistent temperature, humidity 
and flow rate direct into the upper airways. The study 
reported here is a feasibility study of rhinothermy in the 
treatment of the common cold that will inform the design 
of a robust RCT of this treatment. The specific aims of the 
feasibility study were to:
1. estimate the proportions of potential participants af-
ter screening who undergo randomisation, and who 
then complete the study, in turn providing an esti-
mate of the time and resources required to undertake 
an RCT;
2. estimate the SD of the proposed primary outcome 
variable for the RCT, the modified Jackson score,27–29 
so that the sample size for the RCT can be better es-
timated;
3. estimate the likely minimum clinically important dif-
ference (MCID) in modified Jackson score among 
people with the common cold who are eligible to take 
part in the study;
4. estimate the proportions of the different viruses caus-
ing the cold among people with the common cold 
who are eligible to take part in the study;
5. examine the use and tolerability of the modified 
myAIRVO 2 device in those with the common cold.
MethODs
study design
An open-label, randomised, controlled feasibility study.
Participants
Participants with self-reported symptoms of the common 
cold were recruited from the community by advertise-
ment on Wellington Hospital (New Zealand) notice 
boards and intranet, local primary care practices, phar-
macies, student notice boards, social media and from the 
Medical Research Institute of New Zealand database.
Participants were eligible if they were between 16 and 
75 years old, had common cold symptoms for less than 
48 hours at the time of randomisation and a modified 
Jackson score ≥5.28–30 The modified Jackson score is 
calculated from a symptom severity questionnaire that 
consists of eight symptoms: sneezing, nasal discharge, 
nasal congestion, sore/scratchy throat, cough, headache, 
malaise and fever/chills, which are scored on a scale from 
0 to 3 (0=absent, 1=mild, 2=moderate, 3=severe). The 
total score can range from 0 to 24.
Participants were not recruited if they had: (1) an 
immunosuppressive medical condition and/or were 
prescribed immunosuppressive medications; (2) a diag-
nosis of asthma, COPD or other significant respiratory 
conditions; (3) nasal conditions such as a deviated septum 
or chronic rhinitis, which could impair nasal breathing; 
(4) use of cold remedies, for example, decongestants/
cough medicines, linctus/throat lozenges, within 6 hours 
of randomisation; (5) currently using antibiotics or 
inhaled medication; (6) known allergy to ascorbic acid 
(vitamin C); (7) the investigator believed the partici-
pant or their caregiver would be unable to safely use the 
myAIRVO 2 device without medical supervision; (8) had 
any other condition which, at the investigator’s discre-
tion, was believed may present a safety risk or impact the 
feasibility of the study or the study results.
The study was prospectively registered on the Austra-
lian New Zealand Clinical Trials Registry (Trial ID: 
ACTRN12616000470493). The study was sponsored 
by Fisher & Paykel Healthcare, the manufacturer of 
the myAIRVO 2 device. Written informed consent was 
obtained before starting any study specific procedures. 
During the study, participants were able to stop the inter-
vention at any time, without being withdrawn from the 
study. Participants were also able to withdraw from the 
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randomisation and blinding
Participants were randomly assigned in a 2:1 ratio to 
two groups that received either: (1) rhinothermy via the 
modified myAIRVO 2 device, 2 hours per day for up to 
5 days or (2) control medication, vitamin C 250 mg (Heal-
theries, Vitaco Health NZ, Auckland, New Zealand) daily 
for 5 days. The randomisation schedule was computer 
generated by the study statistician, who was not involved 
in study recruitment, procedures or data collection. 
Randomisation was administered by presealed opaque 
envelopes that were opened at the point of randomi-
sation by the investigator. Investigators were blinded to 
allocation until this point. Due to the nature of the inter-
ventions and the unequal randomisation design, partici-
pants, investigators and the study statistician could not be 
masked to treatment allocation.
study procedures
After demographic data were collected, baseline 
common cold symptoms were recorded using the modi-
fied Jackson score, and a physical examination was 
carried out by a doctor. Once eligibility was confirmed, 
pernasal flocked swabs (Copan Diagnostics, California, 
USA) were collected into Universal Transport Medium 
(Roche Diagnostics, Basel, Switzerland). After amplifi-
cation, samples underwent nucleic acid detection using 
multiplex reverse transcriptase-PCR (Roche Diagnostics, 
Basel, Switzerland) in conjunction with the Respiratory 
Pathogens 21 kit (Fast-track Diagnostics, Junglinster, 
Luxembourg). This allowed the detection, if present, of 
influenza A, influenza A (H1N1), influenza B, rhinovirus, 
coronavirus NL63, 229E, OC43, HKU1, parainfluenza 1, 
2, 3, 4, human metapneumovirus A/B, human bocavirus, 
respiratory syncytial virus A/B, adenovirus, enterovirus, 
parechovirus and mycoplasma pneumoniae.
The intervention group received rhinothermy via 
the modified myAIRVO 2 device (PT100AZ, Fisher 
& Paykel Healthcare), a heated breathing tube and 
chamber (900PT551, Fisher & Paykel Healthcare), 
and Optiflow+nasal cannula (OPT944, Fisher & Paykel 
Healthcare; see figure 1). This system is a humidifier 
with an integrated flow generator, able to humidify respi-
ratory gases and deliver them down a heated breathing 
tube through the nasal cannula interface. After randomi-
sation, participants allocated to the intervention group 
used the myAIRVO 2, inhaling 100% humidified air, at 
41°C, at 35 L/min continuously for 2 hours, under super-
vision of investigators at the Clinical Trials Unit (CTU), 
Wellington Hospital (Wellington, New Zealand).
After training on myAIRVO 2 setup and use, partici-
pants were given a modified myAIRVO 2 device to use at 
home according to the same regimen (100% humidity, 
41°C, 35 L/min, 120 min) for up to 5 days depending on 
resolution of symptoms. Participants were encouraged 
to use the device for at least 2 hours per day and longer 
if desired in either a single or repeated administration, 
preferably in the evening. Participants were allowed to 
reduce the flow to 30 L/min or 25 L/min according to 
comfort when at home. After 3 days, participants that were 
randomised to the myAIRVO 2 group were contacted by 
phone to check if they had any adverse events and/or had 
any problems with using the myAIRVO 2.
Participants allocated to the control group received 
their first 250 mg vitamin C tablet in the CTU after rando-
misation, and then at home for a further 4 days. Low-dose 
vitamin C was used as a control. As therapeutic use of 
vitamin C after symptoms develop has not been shown 
to consistently reduce the duration of colds or improve 
cold symptoms,14 participants were not expected to derive 
benefit above that obtained by the placebo effect. The 
low dose of vitamin C used in this study is freely avail-
able in pharmacies in New Zealand but is unlikely to be of 
benefit when taken after symptoms develop, as opposed to 
regular supplementation. Participants who used vitamin 
C returned the bottle for medicines reconciliation.
All participants were requested to complete a symptom 
diary every day for 10 days. The diary comprised a daily 
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modified Jackson score questionnaire and a box to tick 
when they first felt ‘a lot better’ compared with study 
entry. The mean change in modified Jackson score when 
participants felt ‘a lot better’ was used to estimate the 
MCID.
All participants returned to the clinic for a second and 
final visit after day 10 and returned their symptom diary. 
Participants who used myAIRVO 2 returned the device 
and were asked to fill in a tolerability questionnaire about 
their experience. There were nine questions, with partic-
ipants recording their answer on a continuous scale from 
most positive (0) to least positive (100). The questions 
were about: (1) the teaching session; (2) connecting the 
components; (3) cleaning process; (4) level of comfort; 
(5) amount of moisture from the device; (6) weight of the 
nasal interface; (7) noisiness; (8) applying and removing 
the nasal interface; and (9) the likelihood of reusing it in 
the future. Compliance data from the myAIRVO 2 were 
uploaded and analysed.
Outcomes
The primary outcome measure was the proportion of 
recruits who were randomised. Other outcome measures 
included: (1) proportion of randomised participants who 
completed the study; (2) mean and SD of the modified 
Jackson scores from randomisation to 10 days after initia-
tion of the randomised regimen; (3) time until feeling ‘a 
lot better’ compared with study entry; (4) time until reso-
lution of symptoms or symptom score at 10 days postran-
domisation; (5) proportion of organisms identified by 
PCR analysis of nasal swabs taken at baseline; (6) the 
patterns of use of the myAIRVO 2 device, as determined 
by electronic monitoring capabilities of the myAIRVO 2; 
(7) estimated adherence of the control group; and (8) 
myAIRVO 2 tolerability questionnaire results.
sample size and statistical analysis
A sample size of 30 was chosen to:
1. assess the proportion of screened participants who 
were randomised into the trial. If a minimum of 60 
patients were approached, assuming a recruitment 
rate of 50% or less, an achieved participation of 30 
participants has 80% power, one sided alpha of 5% to 
rule out a recruitment rate of less than 34%;
2. estimate the SD of the change from baseline modified 
Jackson score. A sample size of at least 25 has accept-
able precision to estimate a SD based on a χ2 distribu-
tion;
3. estimate the minimum clinically important difference 
in Jackson score. This would require a minimum of 25 
participants for precision (based on a t statistic).
The recruitment and completion rates CIs were esti-
mated by the Clopper-Pearson exact method. Mixed 
linear models with an exponential-in-time covariance 
matrix were used to estimate the differences in modi-
fied Jackson scores by treatment and time. A post 
hoc interaction term tested if the response in modi-
fied Jackson score differed by whether the nasal swab 
results was positive or not. The CI for the SD for the 
change from baseline modified Jackson score was esti-
mated using a χ2 distribution. Logistic regression was 
used to estimate the receiver operating characteristic 
curves for the probability of participants first saying 
they were a lot better compared with the change in 
baseline modified Jackson score at that particular 
time. The times of measurement were chosen so that 
about half of participants reported they had improved 
by that time point. Individual sensitivities and specifi-
cities were calculated for change from baseline modi-
fied Jackson score of between −7 and −4 at these times.
Survival analysis was used to estimate the relationship 
between treatment and time until the participants said 
they felt better and time until the modified Jackson 
score was zero with Kaplan-Meier plots of survival and 
Cox proportional hazards regression to estimate the 
difference in survival. Note that a shorter survival is 
better in this analysis as the event is time to feeling 
better.
SAS V.9.4 was used. Study data were collected and 
managed using REDCap electronic data capture tools 
hosted at the Medical Research Institute of New Zealand.30
Patient and public involvement
No patients or public were involved in setting out the 
research question or developing the outcome measures, 
nor were they involved in developing plans for design or 
implementation of the study. No patients or public were 
asked to advise on interpretation or writing up of results, 
nor was the burden of the interventions on patients 
assessed. The results of the research will be disseminated 




Participant flow through the study is shown in figure 2. In 
all, 79 potential participants were screened for eligibility 
and 30 participants were randomised. All participants 
completed their visits between 12 May 2016 and 13 July 
2016. Participants were predominantly young adults who 
were non-smokers (table 1).
recruitment rate
The recruitment rate was 30/79 (38.0%) with a 95% CI 
27.3% to 49.6%. One of the main reasons for exclusion 
was that participants had symptoms for 48 hours or longer 
at presentation (figure 2). All 30 randomised participants 
completed the study, resulting in a retention rate of 100% 
with a lower 95% confidence limit of 88.4%.
symptoms
Participants had symptoms for a mean of 31 hours 
at presentation, at which time the mean modified 
Jackson score was 11.7 (table 1). There were 27 partici-
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10 days. Table 2 shows the mean (SD), median (IQR) 
and the range of the modified Jackson score from 
baseline to day 10 for both groups. The mean change 
in modified Jackson score from baseline was greater in 
the rhinothermy group than in the control group after 
24 hours and remained greater than the control group 
until day 6 (table 3 and online supplementary table 
S1). Figure 3 shows a plot of the change from baseline 
of the modified Jackson score.
estimation of MCID/substantial clinical benefit
In total, 27 participants reported feeling ‘a lot better’ 
within 10 days of randomisation; 17/20 participants 
from the rhinothermy group and all 10 control group 
participants. Two participants did not fill in the modi-
fied Jackson score on the day they felt ‘a lot better’. 
Therefore, an estimate of the MCID used the scores 
of 25 participants: 16 in the rhinothermy group and 9 
in the control group. We recognised post hoc that the 
threshold ‘a lot better’ corresponded to an estimate of 
substantial clinical benefit rather than the MCID,31 32 
and so we have estimated the change that represents 
substantial clinical benefit. The change from baseline 
modified Jackson score which had the best sensitivity 
and specificity for the participants stating that they felt 
a lot better was between 5 and 6 units on the modi-
fied Jackson Score on days 4 and 5 (table 4). Based on 
this analysis, we propose that a 5-unit change in modi-
fied Jackson score is the substantial clinical benefit 
threshold for this instrument.
The difference in modified Jackson score between the 
rhinothermy group and the control group was greater 
than the substantial clinical benefit threshold on days 3, 4 
and 5, P<0.001 (table 3).
Complete resolution of symptoms, denoted by a 
modified Jackson score of zero, occurred in only 12 
participants within 10 days after randomisation: 10 of 
19 participants who completed the modified Jackson 
score on day 10 in the rhinothermy group and 2 of 10 
in the vitamin C group. The HR (95% CI) for feeling 
‘a lot better’ rhinothermy compared with control was 
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1.33 (0.60 to 2.98), P=0.48, which favoured the rhino-
thermy group. Kaplan-Meier based survival curves are 
shown in figure 4. There were no reported adverse 
events.
estimation of the sD for modified Jackson score
The SDs for the modified Jackson score at days 4 and 5, 
based on the pooled values from t-tests, were 3.8 (95% 
CI 3.0 to 5.2) and 4.8 (3.8 to 6.6) and for change from 
baseline modified Jackson score 3.7 (95% CI 2.9 to 5.0) 
and 4.7 (3.7 to 6.5).
nasal swab viral PCr results
Positive nasal swab PCR for a respiratory virus was found in 
16 participants (53.3%). The organisms found are shown 
in table 5. HRV was the most commonly detected virus 
Table 1 Baseline participant characteristics
Characteristic All participants, n=30 Rhinothermy, n=20 Vitamin C, n=10
Age (years) Mean (SD) 26.0 (8.8) 24.7 (6.4) 28.7 (12.3)
Median (IQR) 23.0 (20.0–31.0) 23.0 (19.5–29.0) 23.5 (21.0–32.0)
Min to max 18.0 to 53.0 18.0 to 38 20.0 to 53.0
BMI (kg/m2) Mean (SD) 24.3 (4.3) 23.9 (3.9) 25.1 (5.0)
Median (IQR) 23.4 (20.9–26.0) 23.3 (20.9–25.9) 24.4 (20.9–26.0)
Min to max 18.4 to 37.2 18.4 to 31.8 20.1 to 37.2
Height (cm) Mean (SD) 172.1 (8.6) 171.8 (7.9) 172.6 (10.4)
Median (IQR) 173.0 (165.0–178.5) 173.0 (168.0–178.3) 173.5 (165.0–179.0)
Min to max 153.0 to 191.0 153.0 to 186.0 156.0 to 191.0
Jackson score Mean (SD) 11.7 (3.6) 11.7 (3.5) 11.8 (4.0)
Median (IQR) 12.0 (9.0–13.0) 11.5 (9.0–14.0) 12.0 (10.0–13.0)
Min to max 7.0 to 21.0 7.0 to 19.0 7.0 to 21.0
Pack years Mean (SD) 0.4 (1.3) 0.5 (1.6) 0.1 (0.3)
Median (IQR) 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.0 (0.0–0.0)
Min to max 0.0 to 6.0 0.0 to 6.0 0.0 to 1.0
Symptom duration (hours) Mean (SD) 31.0 (12.5) 30.5 (12.0) 32.1 (13.9)
Median (IQR) 31.0 (24.0–41.0) 31.0 (24.0–40.5) 34.5 (24.0–46.0)
Min to max 4.0 to 47.0 4.0 to 46.0 8.0 to 47.0
Sex (female), n (%) 19 (63) 13 (65) 6 (60)
Ethnicity, n (%) European 23 (77) 16 (80) 7 (70)
Other 4 (20) 7 (23) 3 (30)
Current smoker, n (%) 4 (13) 4 (20) 0 (0)
BMI, body mass index.





Mean (SD) Median (IQR) Min to max Mean (SD) Median (IQR) Min to max
Baseline n=20/10 11.7 (3.5) 11.5 (9–14) 7 to 19 11.8 (4.0) 12 (10–13) 7 to 21
Day 2 n=19/10 9.4 (3.9) 10 (7–12) 2 to 16 13.5 (3.7) 12.5 (11–15) 10 to 22
Day 3 n=19/10 7.2 (3.7) 7 (4–10) 1 to 14 12.3 (4.0) 11.5 (9–15) 8 to 19
Day 4 n=19/10 4.4 (3.3) 4 (2–7) 0 to 10 10.7 (4.6) 9 (8–15) 5 to 18
Day 5 n=18/10 4.1 (4.8) 3 (2–4) 0 to 17 9.4 (4.9) 10.5 (6–12) 2 to 16
Day 6 n=18/10 2.8 (3.6) 2 (0–5) 0 to 13 7.5 (4.5) 9.5 (3–10) 1 to 13
Day 7 n=18/10 2.4 (2.5) 2 (0–5) 0 to 8 4.8 (2.9) 4 (3–8) 1 to 9
Day 8 n=18/9 1.9 (2.7) 0.5 (0–3) 0 to 10   3 (1.7) 3 (2–4) 0 to 5
Day 9 n=19/10 2.1 (2.9) 1 (0–3) 0 to 11 2.4 (2.1) 1.5 (1–3) 0 to 8
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and was found in one-third of participants. There was no 
evidence of an interaction between the treatment differ-
ence in modified Jackson scores for those that were nasal 
swab positive or negative (P≥0.17 for all time points).
Patterns of rhinothermy and vitamin C use
The mean total use of the myAIRVO 2 device was 
9.9 hours, a mean (SD) of 2.0 (0.85) hours per day. Eight 
participants (40%) did not use the myAIRVO 2 device on 
day 5 and seven participants (35%) used it for less than 
4 days. On the days the myAIRVO 2 was used, the mean 
(SD) use was 2.6 (0.5) hours per day. All participants in 
the control group took all five Vitamin C tablets as per 
protocol (100% adherence).
On day 1 at the clinic, all participants used a flow 
of 35 L/min. On day 2, 13 participants kept using this 
flow rate at home, while 7 participants used a reduced 
flow; a flow of 30 L/min and 25 L/min was used by 3 
and 4 participants, respectively. On days 3, 4 and 5, 
a mixture of the three different flow rates were used 
with a mean flow rate overall of around 32 L/min.
rhinothermy tolerability questionnaire
Tolerability questionnaire results for the myAIRVO 2 
are shown in table 6. The device was reasonably simple 
to connect at home, comfortable to wear and accept-
able with regards to the amount of moisture build-up 
Table 3 Mixed linear model estimates of differences 
between treatments at each time point with baseline 






Two −4.11 (−6.68 to −1.56) 0.002
Three −5.18 (−7.74 to −2.62) <0.001
Four −6.37 (−8.93 to −2.71) <0.001
Five −5.29 (−7.86 to −2.67) <0.001
Six −4.61 (−7.19 to −2.04) <0.001
Seven −2.47 (−5.05 to 0.11) 0.060
Eight −1.10 (−3.73 to 1.54) 0.41
Nine −0.28 (−2.84 to 2.28) 0.83
Ten 0.14 (−2.42 to 2.70) 0.91
Figure 3 Plot of mean (SD) modified Jackson score change from baseline by time and treatment. Solid line represents 
rhinothermy group, while dotted line represents control. Y-axis shows mean modified Jackson score change from baseline. Error 
bars represent one SD from the mean. Mean Jackson score was the same at baseline and day 1 so data are shown from day 2.
Table 4 Sensitivity and specificity for ‘feeling better’ by 
selected change from baseline modified Jackson scores for 
day 4 and day 5
Change from baseline
Improved by participant report
Sensitivity (%) Specificity (%)
Day 4
  -7 9/11 (82) 15/18 (83)
  -6 9/11 (82) 13/18 (72)
  -5 11/11 (100) 12/18 (67)
  -4 11/11 (100) 8/18 (44)
Day 5
  -7 10/17 (59) 10/12 (83)
  -6 12/17 (71) 10/12 (83)
  -5 15/17 (88) 10/12 (83)
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and weight of the nasal interface. It also scored favour-
ably with respect to ease of application but was found 
to be moderately noisy. Overall, participants scored 
a mean (SD) of 32.4 (27.4) units on a scale of likely 
future use where 0 was very likely and 100 was very 
unlikely.
DIsCussIOn
This study has shown that an RCT of rhinothermy via 
high flow nasal cannulae in the treatment of the common 
cold is feasible. The study fully recruited 30 participants 
within an 8-week period, and all completed the study. 
Adherence to rhinothermy treatment was good while 
participants were symptomatic.
This is the first study to investigate rhinothermy using 
the modified myAIRVO 2 device, and strengths include 
the randomised controlled design and the complete 
follow-up of all participants. Participants in this study 
were recruited primarily through social media so the 
results should be generalisable to people in the commu-
nity with symptoms of the common cold.
Three main limitations apply to these results. First, this 
study was designed as a feasibility study that means that 
although the modified Jackson score was a prespecified 
Figure 4 Kaplan-Meier survival curve for time to feeling better. Solid line represents rhinothermy group, while dotted 
line represents control.






Positive 16 (53.3) 11 (55.0) 5 (50.0)
  Human rhinovirus 
(HRV)
10 (33.3) 6 (30.0) 4 (40.0)
  Coronavirus 1 (3.3) 0 (0.0) 1 (10.0)
  Parainfluenza virus 2 (6.7) 1 (5.0) 1 (10.0)
  Respiratory syncytial 
virus
3 (10) 3 (15.0) 0 (0.0)
  Metapneumovirus 1 (3.3) 1 (5.0) 0 (0.0)
Negative 14 (46.7) 9 (45.0) 5 (50.0)
All values given as n (%).
Table 6 Rhinothermy tolerability questionnaire results
Question Mean (SD) Median (IQR)
Min to 
max
Ease of connecting 
components
16.8 (21.6) 5.5 (2.0–22.0) 0 to 67
Ease of cleaning* 16.9 (17.6) 9.5 (3.0–41.0) 0 to 48
Overall comfort 41.3 (23.7) 34.5 (27.5–64.0) 0 to 79
Moisture in nasal 
passages
37.1 (27.2) 29.5 (14.5–55.5) 0 to 92
Weight of nasal 
cannula
29.6 (24.0) 26.0 (6.0–49.0) 0 to 72
Noisiness 54.0 (26.4) 57.5 (35.5–72.0) 0 to 95
Ease of application 14.4 (16.9) 8.0 (2.0–20.0) 0 to 59
Likelihood of reusing 
rhinothermy
32.4 (27.4) 26.5 (11.0–49.5) 0 to 86
All questions were scored from 0 to 100 with low scores 
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efficacy outcome measure, we did not formally specify 
it as the primary outcome measure. Second, due to the 
nature of the intervention, we were unable to blind 
participants and investigators to the allocated interven-
tion and a future study aiming to replicate these results 
should explore the option of sham rhinothermy. Finally, 
the small sample size means that although this study 
found benefits for the new treatment, the results are rela-
tively ‘fragile’, in that the modified Jackson score would 
only need to change in a small number of participants 
who received the rhinothermy intervention to match the 
control group for our conclusions to be different.33 34 A 
formal fragility index cannot be calculated for the change 
in modified Jackson score as it is not a dichotomous vari-
able. The complete follow-up of all participants helps 
protect against this fragility; however, due to the above 
limitations a larger replication study is required.
The development of the myAIRVO 2 device with the 
capacity to deliver 100% humidified air at 41°C at high 
flow direct to the upper airways through wide bore nasal 
cannulae presented the opportunity to investigate the 
efficacy of rhinothermy again, after a lack of RCTs for 
over 20 years. The pragmatic regimen used in this study 
was based on available in vitro and in vivo studies. A 
temperature of 41°C was used as although there is a dose 
dependent reduction in HRV replication up to tempera-
tures of 43°C–45°C,15 16 temperatures of around 43°C are 
prone to cause minor mucosal burns.16 Two-hour sessions 
were used due to the evidence that the shortest duration 
of inhibition of HRV replication is observed with 30 min 
rather than 60 min of hyperthermia in vitro.16 Repeat 
sessions were administered over 5 days, as in vitro the 
effect of hyperthermia is transient, with HRV yields from 
hyperthermic treated cells reaching baseline levels within 
24–48 hours.15
This rhinothermy regimen was well tolerated. Partic-
ipants reported it was comfortable and easy to use and 
apply, although somewhat noisy. These are similar to 
observations made in our earlier tolerability of the 
myAIRVO device in healthy volunteers.26 In the current 
study, participants used the myAIRVO 2 device for 2 hours 
per day on average throughout the 5-day treatment 
period and for 2.6 hours on the days of use. As instructed, 
not all participants used the device late in the treatment 
course once their symptoms had improved. Around a 
third of participants reduced the flow rate to 25 L/min or 
30 L/min suggesting that giving participants the option 
of reducing the flow from the initial 35 L/min, or having 
a lower starting flow, is worthwhile.
Although not a primary outcome for the study, rhino-
thermy with the modified myAIRVO 2 device reduced 
common cold symptoms compared with low-dose vitamin 
C treatment.
The difference between the randomised groups was 
observed within 24 hours, so that the efficacy of single 
dose regimens or sessions over a period of 2–3 days, which 
may enhance its implementation in clinical practice, 
will be worth further study. However, while alternative 
rhinothermy regimens will need to be assessed, our study 
findings suggest that the regimen used in this feasibility 
study should also be used in future RCTs.
Our study has also been informative in terms of the 
likely number of participants required in an RCT. We 
have estimated the change in modified Jackson score 
that denotes substantial clinical benefit to be a 5-unit 
change. Based on the largest confidence limit for an SD 
of 6.6 (from the upper CI of the Jackson score at day 5), a 
sample size of 76 in each group allows the detection of a 
difference of 3.5 units, with 90% power and a type I error 
rate of 5%. Allowing for a 10% dropout rate, a total of 85 
participants would need to be randomised to each group. 
This would require a total of 170 participants in an RCT 
investigating two randomised treatments.
A specific respiratory virus was identified by PCR in 
16/30 (53%) of participants, with the majority being 
rhinovirus. This respiratory virus detection rate was 
comparable with previous studies that report detection 
rates between 43% and 64%.35–37 We found no difference 
in the treatment effect between participants who were 
nasal swab PCR positive or negative, indicating that our 
findings are generalisable to symptomatic common colds 
and not restricted to those with positive virus detection. It 
also suggests that the efficacy may also relate to non-tem-
perature-related antiviral effects, such as humidification 
of the airways and enhanced mucociliary clearance.
COnClusIOn
This study shows that an RCT of rhinothermy with the 
modified myAIRVO 2 device is feasible, that rhinothermy 
is well tolerated and that the estimated change denoting 
substantial clinical benefit for the modified Jackson score 
is a 5-unit change. Our observation that rhinothermy 
improved symptoms now requires replication in a larger 
study of common colds. Investigation of the efficacy 
of rhinothermy in the treatment of influenza is also a 
priority, in view of the temperature-sensitivity of influenza 
viruses38–40 and the major public health burden of influ-
enza worldwide.41 42
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